Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized study on sexual health and quality of life after cervical cancer treatment
2025-521460-36-00Phase 4Authorised
- Sponsor
- IDIBAPS
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of estradiol, progesterone, estradiol valerate, estriol and promestriene in Cervical Cancer (CC), female sexual dysfunction (FSD) and vaginal atrophy (2 arms), sponsored by IDIBAPS. Primary endpoint: Global FSFI score at 12 months after treatment. Planned start May 2025; status: authorised.
02
Drugs
estradiolprogesteroneestradiol valerateestriolpromestriene
03
Conditions
Cervical Cancer (CC)female sexual dysfunction (FSD)vaginal atrophy
Beyond the preview
Go deeper on 2025-521460-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521460-36-00.